文献速递类风湿关节炎

PROMPT试验再分析:甲氨蝶呤预防高危未分化关节炎进展为类风湿关节炎

Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example.
PubMed 文献 · Arthritis Rheumatol · 2017-03-31

该研究重新分析PROMPT试验,用经验证的预测模型筛选基线RA风险≥8分的高危未分化关节炎患者。结果显示,在高危患者中,1年甲氨蝶呤治疗组55%进展为RA,安慰剂组100%进展(P=0.011);MTX组至RA发生时间延长(中位22.5个月 vs 3个月,P<0.001),无药缓解率36% vs 0%(P=0.031)。结论提示充分风险分层对RA预防试验至关重要。

要点

  • 仅约30%未分化关节炎患者进展为RA,低危患者稀释了预防试验的效应。
  • 高危患者中1年MTX使RA发生率从100%降至55%,并延迟发病、提高无药缓解。
  • MTX获益见于ACPA阳性和阴性高危患者,低危患者中未见获益。

核心结论

  • 1年甲氨蝶呤疗程可延迟并预防高危未分化关节炎患者进展为类风湿关节炎。
  • 在RA预防试验中,充分的风险预测对避免假阴性结果至关重要。

研究设计与样本

  • 对PROMPT试验(未分化关节炎中甲氨蝶呤1年疗程 vs 安慰剂)进行再分析。
  • 使用经验证预测模型评估RA风险,预测评分≥8分(阳性预测值≥84%)定义为高危。
  • 在110例PROMPT试验患者中,22例基线为高危,重新评估1年MTX疗程在5年随访中的效果。

主要发现

  • 高危患者中,MTX组11例中6例(55%)进展为RA,安慰剂组11例中11例(100%)进展(P=0.011)。
  • MTX组至RA发生时间中位22.5个月,安慰剂组中位3个月(P<0.001)。
  • MTX组11例中4例(36%)达到无药缓解,安慰剂组0例(0%)(P=0.031)。
  • MTX的获益见于ACPA阳性和ACPA阴性的高危未分化关节炎患者,低危患者中未见获益。
  • 回顾性分析中,110例患者有43例在基线符合2010年ACR/EULAR的RA分类标准。

关键数值与推荐

  • 预测模型评分≥8分对应RA阳性预测值≥84%,作为高危阈值。
  • 高危患者中MTX组RA发生率55% vs 安慰剂组100%(P=0.011)。
  • 至RA发生时间中位22.5个月 vs 3个月(P<0.001)。
  • 无药缓解率36% vs 0%(P=0.031)。

临床怎么用

  • 对未分化关节炎患者应使用经验证预测模型进行RA风险分层,高危者(评分≥8)可考虑1年甲氨蝶呤疗程以延迟或预防RA。
  • 低危未分化关节炎患者从甲氨蝶呤预防中未显示获益,不应仅凭未分化关节炎诊断启动预防治疗。

局限性

  • 再分析仅纳入PROMPT试验中22例高危患者,样本量小。
  • 高危定义基于预测模型评分≥8分,外部适用性需进一步验证。
  • 原始PROMPT试验总体结果为阴性,本研究为事后亚组再分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Prevention of rheumatoid arthritis (RA) was the aim of several trials in undifferentiated arthritis (UA), with overall negative results. As preparatory work has revealed that only ∼30% of UA patients progress to having RA, we hypothesized that inclusion of patients without imminent RA could lead to false-negative results. We undertook this study to evaluate this hypothesis by reinvestigating the Probable Rheumatoid Arthritis: Methotrexate versus Placebo Treatment (PROMPT) trial (a 1-year course of methotrexate [MTX] versus placebo in UA) after excluding patients without a high risk of developing RA. METHODS: A validated prediction model was used to determine the risk of RA in all patients included in the PROMPT trial. Patients with a prediction score of ≥8 (positive predictive value of ≥84% for developing RA) were considered to have a high risk of developing RA. The effect of a 1-year course of MTX during 5 years of follow-up was reinvestigated in these patients. RESULTS: Twenty-two of the 110 patients in the PROMPT trial had a high risk of RA at baseline. In the MTX arm, 6 of 11 patients (55%) developed RA, compared to 11 of 11 patients (100%) in the placebo arm (P = 0.011). Time to RA development was longer in the MTX arm than in the placebo arm (median 22.5 months versus 3 months; P < 0.001). Drug-free remission was achieved by 4 of 11 patients (36%) in the MTX arm compared to 0 of 11 patients (0%) in the placebo arm (P = 0.031). These beneficial effects of MTX were observed both in anti-citrullinated protein antibody (ACPA)-positive and in ACPA-negative UA patients with a high risk of RA, but not in UA patients without a high risk of RA. In retrospect, 43 of 110 patients fulfilled the American College of Rheumatology/European League Against Rheumatism 2010 classification criteria for RA at baseline. In addition, beneficial effects were observed only in patients with a high prediction score. CONCLUSION: A 1-year course of MTX delayed and prevented RA development in high-risk UA patients. This emphasizes the importance of adequate risk prediction in trials that aim to prevent RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Burgers LE, Allaart CF, Huizinga TWJ, et al. Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example. Arthritis Rheumatol. 2017. PMID: 28217975. doi:10.1002/art.40062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。